Ryvu Therapeutics obtains Poland nod for Phase I/II cancer study
The new study will evaluate RVU120’s safety, tolerability, PK, PD and preliminary anti-tumour activity.

The new study will evaluate RVU120’s safety, tolerability, PK, PD and preliminary anti-tumour activity.
AzurRx BioPharma has added two additional clinical trial sites in Poland to reduce any potential patient enrolment delays during the…
Cyxone has announced the screening of the first participant in the Phase II clinical trial to evaluate Rabeximod for treating…
Cyxone is set to initiate a Phase II clinical trial with Rabeximod in moderate Covid-19 patients after it received approval…
WPD Pharmaceuticals and CNS Pharmaceuticals are set to initiate a Phase I clinical trial for Berubicin, an anthracycline, in paediatric…
Moleculin has undertaken and enrolled patients in two anti-cancer clinical trials in Poland.
Orion Biotechnology Canada has completed the acquisition of K2Biomedical for an undisclosed sum.
US-based biopharmaceutical company Ultragenyx Pharmaceutical Inc has announced a public offering of shares of its common stock to raise $175m.
Thank you for subscribing to Clinical Trials Arena